The microbial contract biomanufacturing market is estimated to be worth USD 9.3 billion in 2030, predicts Roots Analysis
Benefits offered by microbial biomanufacturing, such as lowproduction costs and faster development timelines, have led many innovators toadopt these platforms for next generation biologics, offering lucrativeopportunities for CMOs / CDMOs
Roots Analysis is pleased toannounce the publication of its recent study, titled, “MicrobialContract Biomanufacturing Market, 2020-2030.”
The report features an extensive study of the currentmarket landscape and future opportunities associated with the microbialcontract biomanufacturing market. It features a detailed analysis of keydrivers and trends related to this evolving domain. In addition to otherelements, the study includes:
§ Adetailed review of the current landscape of companies offering contractmanufacturing services.
§ Elaborateprofiles of key players that specialize in offering services for contract biomanufacturing.
§ A competitivenessanalysis, highlighting key players engaged in microbial based contractmanufacturing, featuring insightful pictorial summaries and representations.
§ Ananalysis of the partnerships and expansions that have been established in thisdomain, in the recent past.
§ A competitivenessanalysis, highlighting key players engaged in microbial based contractmanufacturing, featuring insightful pictorial summaries and representations.
§ Adetailed proprietary 2×2 representation to assess the current market scenario
§ Ananalysis of the initiatives of big biopharma players engaged in this domain.
§ A detailed market forecast, featuring analysis of thecurrent and projected future opportunity across key market segments (listedbelow)
§ Type of Product
§ API
§ FDF
§ Type of Biologic
§ Proteins
§ Enzymes
§ Growth Hormones
§ Antibody based Drugs
§ Others (plasmidDNA, probiotics, microbiome-based biologics)
§ Type of MicrobialExpression System
§ Bacteria
§ Yeast
§ Others (Algae andfungi)
§ Scale of Operation
§ Commercial
§ Preclinical /Clinical
§ Type of End User
§ Small Companies
§ Mid-sized Companies
§ Large / Very LargeCompanies
§ Key GeographicalRegions
§ North America
§ Europe
§ Asia Pacific
§ Middle East and NorthAfrica
§ Latin America
Transcripts of interviews heldwith the following senior level representatives of stakeholder companies
§ Gaurav Kaushik (ChiefExecutive Officer and Managing Director, MeteoricBiopharmaceuticals)
§ Debbie Pinkston (VicePresident, Sales and Business Development, List Biological Laboratories)
§ Andrea Conforto(Sales and Marketing, Bioservices Director, Olon)
§ Max Rossetto (GeneralManager, Business Development, Luina Bio)
§ Rob van Dijk(Business Development Manager, WACKERBiotech)
Keycompanies covered in the report
§ AGC Biologics
§ Aldevron
§ BioVectra
§ EirGenix
§ Etinpro
§ Eurogentec
§ NorthwayBiotechpharma
§ Ology Bioservices
§ Porton Biopharma
§ Stelis Biopharma
Foradditional details, please visit
https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html oremail sales@rootsanalysis.com
Youmay also be interested in the following titles:
1. DrugRepurposing Service Providers Market, 2020 – 2030
2. AntibodyDiscovery Services and Platforms Market (3rd Edition), 2020-2030
Contact:
GauravChaudhary
+1(415) 800 3415
+44(122) 391 1091
